Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews

Tan, Thuan Tong; Ng, Heng Joo; Young, Barnaby Edward; Khan, Behram; Shetty, Vikram; Azmi, Nura; Clissold, Steve

doi:10.1080/14760584.2023.2191716

Cited by 5 publications

(3 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association of CKD as a factor that can increase time-to-negative swab, to our knowledge, is a new and relevant factor. In fact, previously, several studies showed that patients with CKD had higher mortality and worse outcome compared with patients without [ 28 – 30 ], but, to our knowledge, no studies showed the impact of CKD on the time-to-negative swab. The persistence of SARS-CoV-2 in patients with CKD observed in the present study could be related to an alteration in the immune system due to renal impairment [ 31 ].…”

Section: Discussionmentioning

confidence: 87%

Clinical and epidemiological factors causing longer SARS-CoV 2 viral shedding: the results from the CoviCamp cohort

Grimaldi,

Russo,

Pisaturo

et al. 2023

Infection

View full text Add to dashboard Cite

Introduction The aim of this study was to investigate how long hospitalized patients stayed positive to the nasopharyngeal swab, and what demographic and clinical factors influence the time-to-negative swab. Methods We enrolled in a multicenter, observational, retrospective study involving 17 COVID-19 units in eight cities of the Campania, southern Italy all patients hospitalized from March 2020 to May 2021 diagnosed with Severe Acute Respiratory Distress Syndrome-Coronavirus-2 (SARS-CoV-2) infection for whom time-to-negative swab was available. Results 963 patients were enrolled. We defined three groups considering time-to-negative swab: the first including patients with time-to-negative swab before the 26th day, the second including patients with time-to-negative swab from day 26 to day 39, and the third including patients with time-to-negative swab > 39 days. 721 (74.9%) patients belonged to the first group, 194 (20.1%) to the second, and 52 (5.4%) belonged to the third group. Belonging to group 2 and 3 seemed to be influenced by age (p value < 0.001), Charlson comorbidity index (p = 0.009), arterial hypertension (p = 0.02), cardiovascular disease (p = 0.017), or chronic kidney disease (CKD) (p = 0.001). The multivariable analysis confers a leading role to CKD, with an odds ratio of 2.3 as factor influencing belonging to the groups showing a longer time-to-negative swab. Patients with CKD and diabetes were more frequently in the third group. Discussion Our analysis showed that CKD is a factor related to longer time-to-negative swab, probably because of immunosuppression related to this condition.

show abstract

Section: Discussionmentioning

confidence: 87%

Clinical and epidemiological factors causing longer SARS-CoV 2 viral shedding: the results from the CoviCamp cohort

Grimaldi,

Russo,

Pisaturo

et al. 2023

Infection

View full text Add to dashboard Cite

show abstract

“…Our study and other studies strongly support the monitoring of both humoral and cellular responses to the COVID-19 vaccine in immunocompromised subjects ( 46 ). Furthermore, we suggest a preliminary analysis of B and T cells in patients with immunodeficiency to predict candidates for effective immunization after the vaccine and those that may benefit from alternative preventive approaches ( 47 ). This procedure may be extended to other vaccination protocols for patients with frailty.…”

Section: Discussionmentioning

confidence: 99%

Immunocytometric analysis of patients with thymic epithelial tumors revealed that COVID-19 vaccine booster strongly enhanced the immune response

Cernera,

Gelzo,

De Placido

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundThymic epithelial tumors (TETs) are rare malignancies with heterogeneous clinical manifestations. The high frequency of autoimmune paraneoplastic disorders observed in such patients requires caution when using COVID-19 vaccines. Furthermore, TETs are often associated with severe immunodeficiency, making it difficult to predict vaccine immunization. Therefore, we aimed to evaluate immune response to COVID-19 vaccine in patients with TETs.MethodsWe conducted a prospective study enrolling patients who underwent the SARS-Cov-2 mRNA full vaccine cycle (two doses plus a booster after 6 months of BNT162b2). All patients were enrolled before receiving 1st vaccine dose and were followed over the vaccination cycle for up to 6 months after the booster dose to i) assess humoral and cellular responses, ii) define biomarkers predictive of effective immunization, and iii) evaluate the safety of the vaccine.ResultsAt the end of the full vaccine cycle, 27 (61.4%) patients developed humoral and 38 (86.4%) cellular responses (IFN γ release by stimulated cells) and showed an increase in activated TH1 and TH17 cells, particularly significant after the booster dose. The number of B and T lymphocytes at baseline was predictive of humoral and cellular responses, respectively. Patients with no evidence of tumor lesions had a higher probability of achieving a humoral response than those with evidence of the disease. Furthermore, the percentage of patients with immune-related disorders (75%), particularly Good’s syndrome (47.7%) and myasthenia gravis (29.5%), did not change over the entire vaccine cycle. Overall, 19 of the 44 enrolled patients (43.2%) had COVID-19 during the observation period; none required hospitalization or oxygen support, and no fatalities were observed.ConclusionSARS-Cov-2 mRNA vaccine determines the immune responses in patients with TET, particularly after the booster dose, and in patients with no evidence of tumor lesions. Preliminary analysis of B and T lymphocytes may help identify patients who have a lower probability of achieving effective humoral and cellular responses and thus may need passive immunization. The vaccine prevented severe COVID-19 infection and is safe.

show abstract

“…The risk depends heavily on the extent to which the immune system has been suppressed [ 3 ]. Although vaccinations aim to protect these most vulnerable groups from severe COVID-19, immunocompromised individuals have been shown to exhibit impaired responses to vaccines, including impaired or delayed antibody production [ 4 , 5 ], diminished T-cell responses in some studies [ 6 , 7 ], and greater waning of immunity leading to waning vaccine effectiveness [ 8 , 9 ], and they may not achieve the same level of protection as the immunocompetent [ 10 , 11 ]. This may be due to the immunomodulatory effects of the disease or condition itself or due to treatment with immunosuppressive effects.…”

Section: Introductionmentioning

confidence: 99%

Hybrid Immunity Improves the Immune Response after the Fourth COVID-19 Vaccine Dose in Individuals with Medical Conditions Predisposing to Severe COVID-19

Ekström,

Leino,

Juutinen

et al. 2024

Vaccines

View full text Add to dashboard Cite

Data on immune responses following COVID-19 booster vaccinations and subsequent infections in the immunocompromised are limited. We studied antibody responses after the fourth dose and subsequent infections to define patient groups benefiting most from boosters. Fourth vaccine (booster) doses were, in Finland, first recommended for severely immunocompromised individuals, whom we invited to participate in our study in 2022. We assessed spike protein-specific IgG and neutralizing antibodies (NAb) against the ancestral and Omicron BA.1 strains one month after the fourth dose from 488 adult participants and compared them to the levels of 35 healthy controls after three doses. We used Bayesian generalized linear modeling to assess factors explaining antibody levels and assessed vaccine-induced and hybrid immunity six months after the last vaccine dose. Chronic kidney disease (CKD) and immunosuppressive therapy (IT) were identified as factors explaining sub-optimal antibody responses. The proportion of participants with a normal antibody response and NAbs was significantly lower regarding CKD patients compared to the controls. By the 6-month sampling point, one-third of the participants became infected (documented by serology and/or molecular tests), which notably enhanced antibody levels in most immunocompromised participants. Impaired antibody responses, especially NAbs against the Omicron lineage, suggest limited protection in individuals with CKD and highlight the need for alternative pharmaceutical preventive strategies. Vaccination strategies should take into account the development of robust hybrid immunity responses also among the immunocompromised.

show abstract

Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews

Cited by 5 publications

References 122 publications

Clinical and epidemiological factors causing longer SARS-CoV 2 viral shedding: the results from the CoviCamp cohort

Clinical and epidemiological factors causing longer SARS-CoV 2 viral shedding: the results from the CoviCamp cohort

Immunocytometric analysis of patients with thymic epithelial tumors revealed that COVID-19 vaccine booster strongly enhanced the immune response

Hybrid Immunity Improves the Immune Response after the Fourth COVID-19 Vaccine Dose in Individuals with Medical Conditions Predisposing to Severe COVID-19

Contact Info

Product

Resources

About